Metastatic Unresectable Gastrointestinal Stromal Tumors (GIST) Study CAMN107G2301 Clinical Trial Information

Novartis Clinical Trials and Medical Research Studies Recruiting in the U.S.

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Novartis Clinical Trials provides information about research studies recruiting within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S.

Study Description

Screening

Study Centers

Contact/Consent

Metastatic Unresectable Gastrointestinal Stromal Tumors (GIST) Study CAMN107G2301

The purpose of this clinical trial is to compare the safety and effectiveness of a Novartis investigational drug to imatinib (Gleevec®) in patients with inoperable and/or metastatic Gastrointestinal Stromal Tumors (GIST) who are either newly diagnosed or have experienced recurrences of the disease after stopping treatment with imatinib (Gleevec®). An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3
Participation Duration: Participants enrolling in this study will be required to visit the study center 4 times within the first month. Follow up visits will be required every 3 months until the trial is complete (up to 10 years).
Protocol Number: CAMN107G2301

The next step is to see if you (or the participant) meet the basic criteria required for participation in this clinical trial. Please fill out the questionnaire below to see if you (or the participant) may be suitable for the clinical trial. Your answers to these questions are not retained by this system. You must answer the questions below for yourself, or, you must be the legally authorized representative of the potential participant in order to answer the questions on their behalf. If you (or the participant) do not meet the preliminary qualifications, you may search for other clinical trials of interest or sign up to the Mailing List.

Answers to all questions are required to determine if you meet the preliminary qualifications for the study.

1) Participation in a clinical trial will require travel to a study center where the clinical trial is being conducted. How far would you (or the participant) be willing to travel to a study center to participate in this clinical trial? Please note that participation in these clinical trials may require a number of visits to the study center and travel expenses may not be covered.

25 miles 50 miles 100 miles 150 miles Unlimited

2) Please enter your residential postal zip code.

3) Are you 18 years of age or older?
Yes
No

4) Have you been diagnosed by your physician with metastatic gastrointestinal stromal tumor (GIST)?
Yes
No

5) Have you received prior treatment for your GIST with imatinib (Gleevec®)?
Yes
No

6) Have you received prior treatment with imatinib (Gleevec®) for your GIST, but the disease continued to progress?
Yes
No
I did not receive prior treatment with imatinib (Gleevec®)

7) Are you currently being treated for any other cancer(s) with the exception of skin cancer, cervical cancer, or GIST?
Yes
No

8) Are you currently breastfeeding or pregnant?
Yes
No
Male

	Site Map \| Contact Us \| Find a Clinical Trial \| Mailing List \| Clinical Trial FAQs
	Clinical Trials Glossary \| About Informed Consent \| Medical Research Areas
	Clinical Trial Resources \| How to use this website